Enhancement of replication of Epstein-Barr virus DNA in human lymphoblastoid cell lines by N-methyl-N'-nitro-N-nitrosoguanidine

N-methyl-N'-nitro-N-nitrosoguanidine induces and cooperates with 12-O-tetradecanoylphorbol-1,3-acetate/sodium butyrate to enhance Epstein-Barr virus reactivation and genome instability in nasopharyngeal carcinoma cells

Seroepidemiological studies implicate a correlation between Epstein-Barr virus (EBV) reactivation and the development of nasopharyngeal carcinoma (NPC). Moreover, N-nitroso compounds are known chemical carcinogens in preserved foodstuffs and cigarettes and have been implicated as risk factors contributing to the development of NPC. Here, NPC cell lines latently infected with EBV, NA and HA, and the corresponding EBV-negative NPC cell lines, NPC-TW01 and HONE-1, were used as the model system in this study. We demonstrate that the reactivation of EBV increases with increasing concentrations of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). MNNG at a single non-toxic concentration (0.1μg/ml) did not induce discernible reactivation of EBV, but repeated treatment with this concentration of MNNG significantly induced viral reactivation. Furthermore, low dose MNNG (0.1μg/ml) had a synergistic effect with 12-O-tetradecanoylphorbol-1,3-acetate (TPA)/sodium butyrate (SB) (10ng/ml and 0.75mM, respectively) on EBV reactivation. Through promoter activity assay, MNNG was found to enhance the transcriptional activity of Rta on Rta and Zta promoters. Using siZta to block EBV reactivation, the concomitant induction of genome instability was diminished indicating that reactivation is critical for enhancing genome instability. Co-treatment with TPA/SB and MNNG markedly increased the levels of γH2AX and ROS formation in NPC cells, which may be responsible for the increase of genome instability. Our findings offer a possible mechanism by which N-nitroso compounds induce reactivation of EBV and contribute to malignant progression by enhancing genome instability in NPC cells.

Establishment of an EBV-positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules

We describe a human lymphoblastoid cell line (LCL), called ZS, that originated spontaneously from the cultures of gamma-irradiated (50 Gy) peripheral-blood mononuclear cells of a normal donor. When injected subcutaneously in sublethally irradiated, splenectomized and anti-asialo-GM1-treated nude mice, ZS cells invaded the lymph nodes, that appeared 10 to 50-fold enlarged in all of the mice tested. Furthermore, ZS cells expressed a typical T-cell surface structure, the CD2 molecule, detectable by a variety of different anti-CD2 monoclonal antibodies (MAbs). However, other T-cell markers were not found, with the possible exception of a truncated messenger of the beta chain of the T-cell receptor and ZS cells could be identified as B cells since they (i) expressed a battery of markers of the resting and activated B cells, (ii) displayed a monoclonal rearrangement of the IgH chain locus and (iii) synthesized IgM K molecules. The Epstein-Barr virus (EBV) genome was detected in ZS cells in approximately ten copies per cell by DNA hybridization techniques. Furthermore, the cells were positive for EBV nuclear antigens (EBNA). Western blotting analysis of EBV encoded antigens demonstrated clear differences with those present in the B 95.8 virus-producer cell line, indicating that ZS cells were not infected by EBV in vitro and that they already harbored the virus in vivo. ZS cells formed colonies in vitro with a high cloning efficiency and displayed chromosomal abnormalities in all of the mitoses (karyotype 47, xy, +13, -14, 8p+, 21p+, +m). In spite of these malignant features, ZS cells expressed the full range of EBV latent proteins as usually do "normal" LCSs and did not have any of the chromosomal abnormalities that juxtapose the c-myc oncogene to one of the genes coding for immunoglobulin molecules.

Chemical carcinogen Epstein-Barr virus (EBV) synergism: EBV genome amplification and site-specific mutation during transformation

When treated with chemical carcinogens, peripheral blood lymphocytes (PBLs) from normal adults or patients with acquired immunodeficiency syndrome (AIDS) were more readily transformed than non-treated PBLs into immortalized lymphoblastoid cell lines (LCLs) by the Epstein-Barr virus (EBV, FF41-1). Chemical carcinogens also enhanced spontaneous transformation in both PBL populations. Co-cultivation of lethally ultraviolet (UV)-irradiated uninfected PBLs with EBV-infected PBLs resulted in a dose-related enhancement of transformation, providing evidence that enhancement is in part mediated by carcinogen-induced diffusible trans-acting factors. Analysis of the EcoRI J region of resident EBV genomes showed that LCLs established from carcinogen-treated PBLs frequently had EBV genome amplification higher than that seen in controls. Carcinogen-induced EBV genome amplification was shown to be dose-related. The organization of the terminal region of the EBV genome was analyzed in LCLs derived from carcinogen-treated PBLs and compared to that of FF41-1 and B95-8. LCLs established from N-methyl-N'-nitroso-nitrosoguanidine (MNNG)- and aflatoxin B1-treated PBLs frequently had 2 circular forms of the EBV genome and several linear forms varying by numbers of terminal repeats (TRs) at the 3' and 5' end. This is in contrast to the single episomal circular and linear form of the EBV genome found in the parent FF41-1 and single episomal circular form in control FF41-1-carrying LCLs. Linear forms of the EBV genome were only found in FF41-1-transformed LCLs derived from carcinogen-treated PBLs and were associated with the production of unusually large amounts of infectious EBV. These results demonstrate that chemical carcinogen-mediated enhancement of transformation is accompanied by quantitative and qualitative alterations in the physical structure, organization and expression of the EBV genome which may in turn be the result of a carcinogen-induced cellular SOS response.

The effects of tumor promoters on HTLV-1 expression in a low-virus producer and a non-virus producer cell line

Chemical agents including 5-iodo-2'-deoxyuridine (IUdR), 4-O-methyl 12-O-tetradecanoyl phorbol-13-acetate (TPA), phorbol, and the tumor promoters teleocidin and TPA were tested for their ability to induce Human T-cell leukemia-lymphoma virus Type I (HTLV-I) expression in the low-virus producer MT-1 cell line and in the non-virus producer C63/CRII-2 cell line, which contains at least one integrated HTLV-I genome equivalent per cell [26]. Viral antigen expression increased from 0.3% to 8.7% in the MT-1 cell line after treatment with IUdR, while TPA and teleocidin were marginally or non-effective as inducers. Chemicals did not induce HTLV-I antigen expression in the C63/CI(II-2) cell line. No enhancement of reverse transcriptase activity or alteration of proviral organization was observed after chemical treatment of MT-1 cells.

Studies on chemical carcinogen enhancement of Epstein-Barr virus induced transformation of human neonatal and adult peripheral blood lymphocytes

The effects of a wide range of selected chemical carcinogens on the frequency of Epstein-Barr virus (EBV)-induced transformation have been investigated. The carcinogens tested included direct-acting chemicals and chemicals requiring either activation via reactions with nucleophiles, or cell-mediated enzyme activation. Treatment with some but not all chemicals suspected of being carcinogens resulted in enhanced EBV-induced transformation of neonatal or adult peripheral blood lymphocytes (PBLs). The temporal relationship between carcinogen exposure and EBV infection could dramatically influence the results of the chemical carcinogen-cellular interaction as measured by the cells' ability to subsequently undergo morphologic transformation. This relationship was particularly evident when cells were treated with alkylating agents such as dimethylsulfonate (DMS) or N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Beginning at 24 h, and at later times following EBV-infection, cellular transformation became more resistant to the cytotoxic effects of DMS and, in contrast, more sensitive to the cytotoxic effects of MNNG. These diametrically opposed results clearly demonstrate the ability of EBV infection to alter the response of lymphocytes to chemical carcinogens as measured by transformation. The lymphoblastoid cell lines (LCLs) established from carcinogen-treated PBLs had increased cloning efficiency. Furthermore, using radiolabelled, molecularly cloned subgenomic fragments of EBV DNA and DNA-DNA hybridization, we have been able to detect an increased number of EBV genome equivalents in whole-cell and high-molecular-weight cellular DNA extracted from LCLs established from MNNG as well as DMS-treated PBLs. We propose that carcinogen enhancement of EBV-induced transformation is an example of a two-step mechanism of oncogenic transformation in primary human lymphoid cells. The possible significance of these findings in relation to potential development of lymphomas following EBV exposure will be discussed.